~~<i id='86941FBD97'><strike id='86941FBD97'><tt id='86941FBD97'><pre id='86941FBD97'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

comprehensive

author：knowledge 2025-10-02 18:49:31 - browse：96514

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat the serious liver disease known as MASH.

The pill, called Rezdiffra, is made by Madrigal Pharmaceuticals.

Metabolic dysfunction-associated steatohepatitis, or MASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Neurocrine congenital adrenal hyperplasia trial succeeds

knowledge

hotspot

explore

entertainment

leisure time

hotspot

Whydowegasp,jumpandgopalewhenwe'refrightened?Itallcomesdowntoatiny,almond-shapedstructureinthebraint

WSS

Transgender sports debate: Physicians say bans are health issue

'A game

Fed up with FDA, ALS advocates consider a take

Grad students accuse University of California of wage theft

AMAs digital advisors table RPM coding reform proposal, again

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

focus

comprehensive

knowledge

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Patients, doctors press FTC to beef up hospital merger scrutiny

Heart attack and stroke risk calculators need revising

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Bright Health sells Medicare Advantage business to Molina

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Virginia high school admissions case could be legal follow

Bernie Sanders gets little from pharma CEOs on drug prices

Peter Hotez and the public health issue of online harassment

Artificial intelligence use in health care faces greater scrutiny in 2024

hotspot

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Information blocking fines are now fair game in health care

Fed up with FDA, ALS advocates consider a take

FDA panel to weigh safety of artificial wombs for preterm births

Neurocrine congenital adrenal hyperplasia trial succeeds

ACIP vaccine advisory panel sees its vacancies filled

explore

entertainment

leisure time

hotspot